# A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

> **NCT06723964** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AP Biosciences Inc.** · enrollment: 35 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AP505

## Key facts

- **NCT ID:** NCT06723964
- **Lead sponsor:** AP Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-30
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-11-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723964, "A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06723964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*